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Abstract
Background: Efficacious strategies for the primary prevention of coronary heart disease (CHD) are underused, and,
when used, have low adherence. Existing efforts to improve use and adherence to these efficacious strategies have
been so intensive that they are impractical for clinical practice.
Methods: We conducted a randomized trial of a CHD prevention intervention (including a computerized decision
aid and automated tailored adherence messages) at one university general internal medicine practice. After
obtaining informed consent and collecting baseline data, we randomized patients (men and women age 40-79
with no prior history of cardiovascular disease) to either the intervention or usual care. We then saw them for two
additional study visits over 3 months. For intervention participants, we administered the decision aid at the primary
study visit (1 week after baseline visit) and then mailed 3 tailored adherence reminders at 2, 4, and 6 weeks. We
assessed our outcomes (including the predicted likelihood of angina, myocardial infarction, and CHD death over 10
years (CHD risk) and self-reported adherence) between groups at 3 month follow-up. Data collection occurred from
June 2007 through December 2009. All study procedures were IRB approved.
Results: We randomized 160 eligible patients (81 intervention; 79 control) and followed 96% to study conclusion.
Mean predicted CHD risk at baseline was 11.3%. The intervention increased self-reported adherence to chosen risk
reducing strategies by 25 percentage points (95% CI 8% to 42%), with the biggest effect for aspirin. It also changed
predicted CHD risk by -1.1% (95% CI -0.16% to -2%), with a larger effect in a pre-specified subgroup of high risk
patients.
Conclusion: A computerized intervention that involves patients in CHD decision making and supports adherence
to effective prevention strategies can improve adherence and reduce predicted CHD risk.
Clinical trials registration number: ClinicalTrials.gov: NCT00494052
Background
Efficacious strategies for the primary prevention of cor-
onary heart disease (CHD) (including aspirin, blood
pressure and cholesterol medicine, and smoking cessa-
tion) reduce the relative risk of CHD events by 20-50%
each [1-4]. However, these strategies are underused in
clinical practice [5-9] and have low rates of adherence
[10].
Multiple systematic evidence reviews [11-15] and a
recent meta-review [16] have demonstrated that many
types of interventions yield small to moderate improve-
ments in medication use and adherence. A common
observation, however, is that efficacious interventions
are resource-intensive. For instance, the most efficacious
interventions for hypertension and cholesterol medica-
tion adherence include multiple telephone or in-person
counseling sessions delivered by researchers, nurses, or
pharmacists with or without the addition of other
approaches, such as medication reminders [13,17]. This
led one recent systematic review to conclude that
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medication adherence can be improved consistently
within the resources available in clinical practice.” [13]
Given limited resources for counseling in clinical prac-
tice [18], alternatives to medication use and adherence
counseling must be considered and tested. Two such
options are decision aids and automated message
libraries. Decision aids employ interactive media to con-
vey health information, help patients clarify their values,
and choose health options that are consistent with their
values. Automated message libraries generate individu-
ally tailored messages that can be used to address speci-
fic patient barriers, provide skill building, and give
information about ancillary resources [19]. Both have
the potential to alleviate provider burden for counseling.
However, their role in promoting medication initiation
and adherence is largely untested [13,20-22].
This paper reports on the effects of an intervention
designed to promote initiation and adherence to effica-
cious strategies for the primary prevention of CHD. The
intervention includes both a decision aid and a series of
automated tailored adherence reminders.
Methods
Overview
To test the feasibility of delivering the intervention in
clinical practice and the effect of the intervention on
important efficacy outcomes, the research team con-
ducted a randomized trial at one university general inter-
nal medicine practice between June 2007 and December
2009. After collecting baseline data, study staff rando-
mized participants to either the intervention or usual
care, and then saw them for two additional study visits
over 3 months. (See Figure 1) The University of North
Carolina at Chapel Hill’s Biomedical Institutional Review
Board (IRB) approved and monitored this study.
Setting
The research team conducted this trial in one university
internal medicine practice staffed by 94 physicians,
including 18 attendings and 76 residents who were not
part of the study team and were eligible for participa-
tion. 94% of eligible attendings and 32% of eligible resi-
dents attended a study education session, agreed to
participate, and allowed their patients to be enrolled.
The 1-hour education session encouraged physicians to
1) engage their patients in decisions about CHD preven-
tion and 2) use readily available resources to support
adherence. Prior to the education session, physicians
gave written informed consent.
Patient Population
Patients were eligible to participate if they were presenting
for routine care with an enrolled physician; were between
the ages of 40-79 years; had no prior history of cardiovas-
cular disease, diabetes mellitus, or other serious medical
condition that limited their life expectancy to less than 5
years; and were at moderate (6-10%) or high risk (> 10%)
of CHD over 10 years based on a Framingham risk equa-
tion [23]. Patients were excluded if they were presenting
for their first visit, had no cholesterol check within the
past 18 months, were unable to speak or read English, or
had extreme elevations of systolic blood pressure (> 180
mmHg) or cholesterol (> 300 mg/dL).
Patient Recruitment and Enrollment
To recruit patients, study staff identified all age eligible
patients returning for visits with enrolled physicians.
After reviewing patients’ charts, staff mailed recruitment
letters to potentially eligible patients and made 3
attempts to call patients who did not “opt-out” of
further contact by returning an opt-out postcard. When
they reached patients by phone, staff reassessed eligibil-
ity and arranged a visit for interested patients.
Patients presented for their initial study visit at least
one week prior to a regularly scheduled clinic visit with
an enrolled physician. During this visit, patients pro-
vided written informed consent; filled out a baseline sur-
vey about their demographics, medication use, and plans
and self-efficacy for risk reduction; and had their CHD
risk factors assessed. Study staff used baseline risk factor
assessments to recalculate baseline predicted CHD risk
and assure study eligibility.
Randomization and Blinding
Following enrollment, patients were randomized by
study staff who accessed an online randomized schedule.
Staff told patients only that they were participating in a
study about “prevention of heart disease.” Physicians
were not blinded and saw patients in both the interven-
tion and control group.
Patient-Directed Intervention
The patient-directed intervention consisted of two com-
ponents: a computerized decision aid to promote initia-
tion of effective CHD prevention strategies, and a series
of automated mailed tailored messages to promote
adherence. Intervention components were based on the
Integrative Theory, Protection Motivation Theory, and
Self-Determination Theory as previously described [24].
Further, they were designed at a 6-8th grade reading
level and pre-tested using cognitive and usability testing.
Decision Aid
The web-based decision aid, called Heart to Heart, had
five main functions: it 1) calculated patients’ overall risk
of CHD events in the next 10 years using a continuous
Framingham equation [23]; 2) educated patients about
CHD, their predicted global CHD risk, their risk factors,
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reducing strategies (aspirin, cholesterol medication,
hypertension medication, and smoking cessation); 3)
helped patients clarify their values [25]; 4) encouraged
them to choose risk-reducing strategies that would be
acceptable and feasible to them for long-term CHD risk
reduction; and 5) coached them to communicate their
decisions with their physicians by providing audio clips
about ways to overcome common communication bar-
riers. Investigators pilot-tested a previous version of the
decision aid [26] and studied its effects with and without
the values clarification section [25]. The coaching portion
has not been independently described or tested; a more
detailed description is provided in Additional File 1.
186 patients agreed to participate  
79 control 
(Usual care) 
1 visit no show 
1 declined further 
participation 
3 false inclusions* 
1170 patients eligible based on chart review  
261 refused 
192 no contact 
250 visit conflict 
188 No RA 
available 
93 Other 
21 ineligible 
(CHD risk <6%) 
165 participants randomized  
81 intervention  
(Decision aid intervention) 
2 visit no shows 
2 declined further 
participation 
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Figure 1 Study Flow Diagram. Abbreviations: RA = Research Assistant; CHD = Coronary Heart Disease. * Ineligible after measuring baseline risk
factors (CHD risk < 6%).
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The tailored messaging system helped patients circum-
vent self-identified barriers and gain the necessary
resources and skills for adherence. This automated mes-
saging system included a library of 76 unique messages,
which could be combined in over a million combina-
tions in response to a few brief survey questions. The
basic logic of this tailoring is shown in Figure 2; more
detailed content is provided in Additional File 2. In
brief, messages were first tailored based on patients’
intentions to start one or more of the most effective risk
reducing strategies (e.g. take aspirin, cholesterol medica-
tion, hypertension medication, or stop smoking). For
patients who planned to start risk reducing strategies,
messages then addressed self-identified barriers to
adherence, including cost; side effects; difficulty remem-
bering to take medications; difficulty accessing care;
and, for smokers, behavioral challenges in stopping
smoking. For patients who did not plan to start risk
reducing strategies, messages encouraged reconsidera-
tion of the need for global CHD risk reduction and
addressed self-identified barriers to risk reduction. Based
on the logic in Figure 2, each participant in the inter-
vention group received a series of 3 computer-generated
mailed tailored adherence newsletters.
Delivery of the Intervention and Surveys
The primary study visit occurred in conjunction with a
previously scheduled visit with a participant’s usual physi-
cian. Participants randomized to the intervention group
presented 45 minutes early to their clinic visit to view the
decision aid and received a list of their risk factors to get
them started. They then self-entered their risk factors and
navigated the decision aid on their own using a computer
stationed in a private room in the clinic. They had access
to research staff at all times for questions about navigation.
After viewing the decision aid, participants proceeded to
their clinic visit. Participants randomized to the control
group did not receive a decision aid and proceeded
directly to their clinic visit. Following the clinic visit, a
research assistant administered surveys to both interven-
tion and control patients to assess their plans for CHD
After visiting with your doctor, how are you planning to lower your chances of heart disease?  
Take aspirin, blood pressure medicine, 
cholesterol medicine
Stop smoking  Other (e.g. diet, exercise, other, 
nothing) 
How concerned are you that the following might get 
in the way?
   
 
Why did you decide against (aspirin/blood 
pressure medicine/ cholesterol medicine/ 
stopping smoking)?
  
1. Cost* 
2. Side effects from    
    medicine 
3. Remembering to take     
    medicines† 
4. Difficulty with access   
    to provider for   
   questions  
1. Cost* 
2. Side effects from  
    medicine‡ 
3. Behavioral challenges 
    a. Withdrawal symptoms 
    b. Situations where others  
        smoke 
    c. Remembering to take  
        medicine 
4. Difficulty with access to  
    quit smoking resources 
1. Don’t think CHD chances are high  
    enough 
2. Provider and I disagree 
3. Need time to decide 
4. Don’t like taking medicine 
5. No option meets my needs 
6. Not enough support 
7. Reduce enjoyment of life 
8. Other things to take care of first 
 
Three tailored messages generated in order of chosen barriers listed above§ 
Figure 2 Basic Logic and Structure of Tailored Messages. Abbreviations: CHD = Coronary Heart Disease. * Further tailored on whether
participant has prescription drug plan. † Further tailored on self-reported adherence at baseline. ‡ Further tailored on which smoking cessation
medication was prescribed. § If fewer than 3 barriers identified, patients received default messages: “Plan Ahead"; “Check on Your Progress
Regularly"; and “Eat Right and Be Active”.
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sages to participants in the intervention group approxi-
mately 2 weeks, 4 weeks, and 6 weeks after their initial
study visit.
Approximately 3 months after the initial study visit, all
participants presented for a final study visit and final
measures.
Measures
Feasibility of Intervention Delivery
Investigators measured the feasibility of intervention
delivery by measuring the total time participants spent
with the decision aid, whether or not participants
required assistance with the decision aid, and the time
spent by the research assistant preparing and mailing
tailored messages.
Change in Predicted Global CHD Risk
Investigators measured predicted global CHD risk (i.e.
risk of angina, myocardial infarction (MI), and CHD
death over 10 years) using a well-validated Framingham
risk equation [23], that combined information about a
patients’ age, gender, smoking history, diabetes status,
systolic blood pressure level, total and HDL-cholesterol
levels, and left ventricular hypertrophy status in a multi-
variate equation. Following a precedent set by other
researchers [27-30], the research team assumed that the
benefits of medication are reasonably captured by enter-
ing revised risk factor data into the Framingham equa-
tion. Because the effect of aspirin use on CHD risk is
not accounted for by the Framingham equation, the
team additionally performed a priori-specified modeling
of the effects of aspirin by applying a 28% risk reduction
[1] to the calculated CHD risk. This modeling mirrored
the modeling of aspirin effects participants saw in the
decision aid [31]. To be consistent with a more recent
meta-analysis published during the study period [32],
the team also performed a sensitivity analysis, recalculat-
ing predicted global CHD risk using a 23% risk reduc-
tion for men and a 0% reduction for women. The team
also performed sensitivity analyses to determine whether
modeling the effects of each CHD risk reducing strategy
(aspirin, blood pressure medicine, cholesterol medicine,
and smoking cessation) on baseline CHD risk produced
different results than recalculating risk as described
above. For this analysis, the team multiplied baseline
Framingham risk scores by a 28% relative risk reduction
for aspirin users, a 25% relative risk reduction for blood
pressure medicine users, a 30% relative risk reduction
for cholesterol users, and a 50% relative risk reduction
for those who stopped smoking [1-4]. Modeling medi-
cine effects may allow investigators to estimate the full
benefits of medicines (including those which accrue out-
side changes in traditional CHD risk factors), however,
modeling doesn’t adequately account for variance in
medicine adherence or the effects of other co-interven-
tions (such as diet and exercise) that impact CHD risk.
Intent to Start Any Effective CHD Risk Reduction Strategy
The research team measured intent to start any effective
risk reducing strategy after the primary study visit by
asking participants whether or not they planned to initi-
ate aspirin or smoking cessation or initiate or increase
blood pressure or cholesterol medication.
Self-reported Adherence
Adherence was assessed at 3 months both by self-
reported adherence to any new or escalated risk reduc-
tion strategy and by self-reported adherence to each indi-
vidual strategy separately. To verify self-reported
adherence, the team then examined changes in CHD bio-
markers (including blood pressure and total and HDL
cholesterol) among those who self-reported adherence.
CHD Risk Factors
Study staff measured CHD risk factors at baseline and
follow-up study visits using well-defined protocols. They
measured blood pressure using a non-invasive oscillo-
metric automatic monitor (Omron HEM-907) after the
patient had been seated for at least 5 minutes. They
averaged three measurements taken at one minute inter-
vals, and defined hypertension as a systolic measure-
ment > 140 mm Hg [33]. They measured serum total
and HDL cholesterol levels at the UNC Hospitals’
McLendon Laboratory using enzymatic calorimetric
testing (Roche Diagnostics Corporation) and defined
high cholesterol as a total/HDL cholesterol ratio > 4
[34]. Finally, staff measured smoking status by self-
report with confirmation by urine dipstick using the
NicAlert test strips (Jant Pharmacal; Encino, CA). A test
strip measure of 3 or higher (cotinine concentration >
100 ng/mL) is a positive indication of tobacco use.
Statistical Considerations
Sample Size
Sample size was not based on hypothesis testing, but
instead on a reasonable estimation of the sample size
necessary to 1) assess the feasibility of the intervention,
and 2) determine the effect sizes for the main effects of
the intervention.
Analysis Methods
All data analysis was performed using SAS (Cary, NC)
software. To examine the effects of the intervention on
primary and secondary efficacy outcomes, including pre-
dicted CHD risk, intent to start therapy, self-reported
adherence to therapy, and changes in risk factors, investi-
gators used mixed effects models. The study team used a
logistic link function for binary outcome variables. They
used linear mixed effects models for the continuous out-
come variables. Each model included the intervention,
education as fixed effects and physicians as random effects.
Models on CHD risk factors additionally included baseline
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As a check on self-reported adherence, analyses examined
the effect of self-reported adherence on CHD risk factors
among those who self-reported adherence to blood pres-
sure and cholesterol medication.
To test intent for CHD risk reduction and self-
reported adherence as mediators of the intervention’s
effect on predicted CHD risk, the team used generalized
linear mixed effects models and the Baron and Kenny 4-
step approach to mediation analysis [35].
Results
The study sample included 24 eligible physician partici-
pants who had patients enrolled in the study and 160
patient participants who agreed to participate and were
randomized (see Table 1), 81 in the intervention group
and 79 in the control group. The study lost 6 patient
participants during follow-up, resulting in a 96% follow-
up rate (see Figure 1).
Feasibility of Intervention Delivery in Practice
Intervention participants spent an average of 12 minutes
(range: 1-45 minutes) with the decision aid and were
able to navigate it with minimal assistance. Tailored
message mailings took research assistants less than 5
minutes per participant.
Effect of the Intervention on Predicted Global CHD Risk
At follow-up, participants in the intervention group had a
statistically significant lower mean 10-year predicted CHD
Table 1 Baseline Participant Characteristics
Characteristic Total Group (N = 160*) Intervention Group (N = 81) Control Group (N = 79)
Mean age 63 63 64
Female 28% 27% 28%
Race:
White 86% 88% 84%
Black 10% 10% 10%
Education:
At least some college 90% 98% 82%†
Enrolled in a prescription drug plan 90% 91% 89%
Missed medicine in the last month:
Less than 5% of time 92% 90% 95%
6-25% of time 4% 4% 3%
26-50% of time 2% 3% 2%
51-75% of time 0% 0% 0%
76-95% of time 1% 1% 0%
More than 95% of time 1% 1% 0%
Have potentially modifiable CHD risk factors:
Blood pressure > 140/90 (mmHg) 36% 35% 37%
Total cholesterol/HDL ratio > 4 54% 53% 51%
Smoker 13% 14% 13%
Not using aspirin, but eligible for it 50% 54% 47%
Mean systolic blood pressure (mmHg) 136.9 136.2 137.6
Mean diastolic blood pressure(mmHg) 81.0 81.5 80.4
Mean total cholesterol (mg/dL) 201.1 204.9 197.1
Mean HDL cholesterol (mg/dL) 53 54.1 51.9
Mean predicted CHD risk over 10 yrs 11.3 11.2 11.4
# of possible intervention options for CHD risk:‡
0 10% 12% 8%
1 28% 28% 27%
2 47% 40% 54%
3 16% 20% 11%
40 % 0 % 0 %
Have self-efficacy to lower at least 1 CHD risk factor 98% 99% 96%
Are planning best evidence interventions§ 27% 28% 25%
Abbreviations: CHD = Coronary heart disease; HDL = high density lipoprotein
* 160 participants at baseline; 3 missed both primary and follow-up study visits and 3 declined further participation after the primary study visit
† Statistically different between the intervention and control groups (p < .01)
‡ This includes hypertension medicine, cholesterol medicine, smoking cessation, and aspirin
§Proportion planning to do any of the following intervention options that are supported by the highest quality of evidence: hypertension medicine, cholesterol
medicine, smoking cessation, and aspirin
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lute difference -1.1%; 95% CI -2.0% to -.16%). In a pre-spe-
cified high risk subgroup, the effect was larger, but not
statistically significant due to the smaller sample (see
Table 2). In sensitivity analyses assuming a 23% relative
risk reduction for aspirin for men and a 0% relative risk
reduction for aspirin for women, results were similar in
magnitude (adjusted absolute difference, entire sample:
-1.0%; 95% CI -2.0% to 0.02%; high risk subgroup: -1.53%;
95% CI -3.47% to 0.42%; moderate risk subgroup: -0.95%;
95% CI -2.33% to 0.44%), but not statistically significant.
In sensitivity analyses that modeled the effect of risk-redu-
cing strategies (rather than recalculating risk), results were
also similar in magnitude (adjusted absolute difference,
entire sample: -1.0%, 95% CI -2.4% to 0.30%; high risk sub-
group: -1.5%, 95% CI -3.7% to 0.70%; moderate risk sub-
group: -0.85%. 95% CI -1.5% to -0.16%), although again
not statistically significant.
Effect of the Intervention on Intent to Start Any Effective
CHD Risk Reducing Strategy
Compared with the control group, participants in the
intervention group had significantly higher intentions to
start or increase any of the effective CHD risk reducing
therapies promoted by our intervention (control 42%,
intervention 63%; absolute difference 21%; 95% CI 5% to
37%; adjusted p < 0.01). Increases in overall intent pri-
marily resulted from increases in intent to take aspirin
(control 24%, intervention 43%; absolute difference 19%;
95% CI -1 to 39%) and cholesterol medication among
those with abnormal cholesterol (control 9%, interven-
tion 39%; absolute difference 30%; 95% CI 14 to 46%).
Effect of the Intervention on Self-reported Adherence to
Chosen Risk Reducing Therapies
Patients in the intervention group also had higher self-
reported adherence to the chosen risk reducing thera-
pies promoted by the intervention (adjusted absolute
difference +25%; p < 0.01; see Table 3). Most of the
interventions’ effect on adherence seemed to be through
aspirin use (+36%; 95% CI 17% to 55%; p < 0.01), with
little effect on blood pressure or cholesterol medication,
however, the sample sizes for these latter estimates were
small and underpowered.
Effect of the Intervention on CHD Risk Factors
In subgroup analyses, the effect of the intervention on
CHD risk factors varied (see Table 4). The intervention
tended to reduce blood pressure (adjusted absolute dif-
ference, systolic blood pressure: -6.6 mm Hg; 95% CI
-14.3 to 1.2; diastolic bloodp r e s s u r e :- 1 . 2m m H g ;9 5 %
CI -5.2 to 2.8), although results didn’t achieve statistical
significance. It, however, had no effect on total or HDL
cholesterol or smoking, although subgroups were small
and underpowered.
Analyses to confirm self-reported adherence did con-
firm an effect of self-reported adherence on systolic
blood pressure (-8.6 mmHg, 95% CI -14.8 to -2.3) and
total cholesterol (-45.6 mg/dL, 95% CI -75.2 to -16.1) in
individuals self-reporting adherence to blood pressure
and cholesterol medications respectively.
Potential Mediators of Intervention Effect
In mediation analysis, adding intentions for CHD risk
reduction to the model testing the relationship between
the intervention and predicted CHD risk reduced the
difference in predicted CHD risk by 0.18 absolute per-
centage points, while adding self-reported adherence to
the model reduced the difference in predicted CHD risk
by 0.22 absolute percentage points.
Discussion
At 3-month follow-up, a computerized intervention
designed to promote CHD prevention medication use
and adherence increased self-reported adherence by 25
percentage points and reduced 10-year predicted global
CHD risk by 1.1 percentage points, with a larger effect
seen in a pre-specified high risk sub-group. The effect
on predicted CHD risk was mediated, in part, by intent
to reduce CHD risk and by self-reported adherence.
These findings are similar to those reported in pre-
vious studies of more resource-intensive interventions
Table 2 Effect of Heart to Heart Intervention on CHD Risk at Follow-up
Control group (N =
77)
Intervention group (N =
77)
Absolute difference (95%
CI) *
Adjusted absolute
difference†
Total group
(n = 154)
10.4% 9.1% -1.3%
(-3.0% to 0.40%)
-1.1%
(-2.0% to -0.16%)
Moderate risk at baseline (6-
10%)
(n = 82)
7.9% 7.0% -0.93%
(-2.4% to 0.51%)
-0.75%
(-1.6% to 0.13%)
High risk at baseline (> 10%)
(n = 72)
13.2% 11.4% -1.72%
(-3.83% to 0.38%)
-1.4%
(-3.2% to 0.39%)
Abbreviations: CHD = Coronary heart disease
*Adjusted for random effects of clustering within physician
†Adjusted for baseline CHD risk, education level, and random effects of clustering within physician
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reviews have shown 10-25 absolute percentage point
increases in adherence, with the largest effects in studies
using multiple telephone or in-person counseling ses-
sions [17]. Furthermore, a recent systematic evidence
review found that global risk information, in repeated
doses or with repeated counseling, reduced predicted
CHD risk by 0.2 to 2 absolute percentage points [36].
What is noteworthy about this study is that it achieved
its effects using a computerized decision aid and auto-
mated message library to perform the functions of edu-
cation and counseling.
Also noteworthy about this study are the reported
effects of the intervention on aspirin adherence. Given
the risk based recommendations for aspirin therapy [37]
and individuals’ desire for inexpensive, familiar, trusted
interventions [24], it is not surprising that the interven-
tion had its greatest effect on initiation of and adherence
to aspirin.
What is somewhat surprising about this study is the
apparent lack of effect of our intervention on choles-
terol-lowering medication adherence. Not only are cho-
lesterol guidelines risk-based, but a recent systematic
review [36] found consistent reductions in total and
LDL cholesterol in patients who received predicted
CHD risk information and counseling. We suspect the
lack of effect of the intervention on cholesterol is due in
large part to the small number of participants (n = 20)
choosing, initiating and adhering to cholesterol therapy,
which limits the ability to detect any effect.
To better understand the effects of our intervention,
investigators performed mediation analyses. These
Table 3 Proportion of Participants Adhering to their Chosen CHD Risk Reduction Therapy at 3-month Follow-up
Chosen therapy (number in
analysis)
Control
% (n/N)
Intervention
%(n/N)
Absolute difference
(95% CI) (p-value)*
Odds ratio
(95% CI)*
Adjusted absolute
difference, p-value†
Adjusted odds
ratio (95% CI) †
Any chosen therapy promoted by
intervention (n = 149) ‡
34%
(25/73)
59% (45/76) 25%
(8% to 42%)
(p < 0.01)
2.8
(1.3 to 5.9)
25%, p < 0.01 3.4
(1.4 to 6.9)
Any chosen therapy, including
other§ (n = 154)
68%
(52/77)
83% (64/77) 16%
(4% to 28%)
(p = 0.02)
2.4
(1.2 to 4.9)
14%, p = 0.04 2.2
(1.0 to 4.8)
Take aspirin (n = 51) 58%
(11/19)
94% (30/32) 36%
(17% to 55%)
(p < 0.01)
10.9 (2.0 to
59)
39%, p < 0.01 12.8
(2.0 to 84)
Take cholesterol medicine (n =
20)
83%
(5/6)
86% (12/14) 3%
(-28% to 33%)
1.2
(0.1 to 12.3)
––
Take blood pressure medicine (n
= 21)
92%
(11/12)
100% (9/9) 8%
(-9% to 25%)
–|| ––
Stop smoking (n = 13) 20% (1) 25% (2) –– – –
Abbreviations: CHD = Coronary Heart Disease
* Adjusted for clustering within physician
† Adjusted for education level, and random effects of clustering within physician
‡“ Any chosen therapy promoted by intervention” includes hypertension med, cholesterol med, smoking cessation, aspirin
§ “Any chosen therapy, including other” includes hypertension med, cholesterol med, smoking cessation, aspirin, diet, and physical activity
|| Unable to calculate due to small cell size
Table 4 Effect of Heart to Heart Intervention on CHD Risk Factors at 3-month Follow-up*
Risk factor (number with risk
factor at baseline)
Control group Mean
(n or n/N)
Intervention group Mean
(n or n/N)
Absolute difference
(95% CI) †
Adjusted absolute
difference (95% CI) ‡
Systolic blood pressure, if HTN (n =
53)
146.6 (27) 139.3 (26) -7.21
(-14.4 to -0.03)
-6.6
(-14.3 to 1.2)
Diastolic blood pressure, if HTN (n =
53)
80.2 (27) 80.4 (26) +.27
(-4.24 to 4.79)
-1.2
(-5.2 to 2.80)
Total cholesterol, if abnormal
cholesterol (n = 67)
196 (33) 203 (34) +7.02
(-14.8 to 28.8)
+8.0
(-12.0 to 28.1)
HDL, if abnormal cholesterol (n =
67)
42 (33) 46 (34) +4.3
(0.08 to 8.53)
+1.1
(-3.08 to 3.37)
% Smoking, if smokers (n = 13) § 100% (5/5) 88% (7/8) –
Abbreviations: HTN = hypertension; HDL = high density lipoprotein
* Among individuals with baseline risk factors
† Confidence intervals adjusted for random effects of clustering within physician
‡Confidence intervals adjusted for education, baseline risk factor levels, and random effects of clustering within physician
§ Confirmed by urinary cotinine
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Page 8 of 10analyses suggest that both intent to reduce CHD risk
and self-reported adherence to medications partially
mediate reductions in 10-year predicted CHD risk. The
proportional effects, however, are small (~20%), raising
questions about other potential mediators such as diet
and physical activity.
Interpretation of these findings should proceed with
acknowledgement of the following limitations. First, this
was a relatively small study not designed to look at sub-
group effects. Subgroup analyses are small and under-
p o w e r e d ,a n ds h o u l db eu s e do n l yf o rh y p o t h e s i s
generation. Second, physicians saw patients in both the
intervention and control groups, which may have
resulted in contamination between study groups. This
may have reduced the effects of our intervention. Third,
the effect of the intervention was diluted by the pre-
sence of participants (10%) who had no options for
CHD risk reduction. Fourth, investigators measured
adherence primarily by self-report (although with corre-
lation with biomarkers). Based on studies comparing
objective and subjective measures of adherence [38], it
is likely we slightly overestimated adherence. Fifth,
although randomization is expected to result in equally
distributed characteristics between the intervention and
control groups, the difference in education between
groups raises questions about unmeasured confounders.
Sixth, the study team conducted this study in one aca-
demic medicine clinic, and results might not generalize
to other clinics, physicians, or patient populations.
Finally, this was a short-term study with only 3 months
of follow-up; longer follow-up likely would affect results.
Conclusions
Limitations aside, the results of this study preliminarily
suggest that an adherence intervention employing a com-
puterized decision aid and automated adherence messages
can increase patients’ adherence and reduce CHD risk.
This result should be confirmed in larger and broader
populations with longer term follow-up. Additionally,
future studies should consider additional implementation
issues, such as cost, cost-effectiveness, and alternate
mechanisms of delivery (e.g. via electronic health record).
Additional material
Additional file 1: Coaching Portion of the Heart to Heart Decision
Aid.
Additional file 2: Content of Tailored Adherence Messages.
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